Deans' stroke musings: Lost Protein Could Prevent Hardening of the Arteries

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Tuesday, September 23, 2014

Lost Protein Could Prevent Hardening of the Arteries

What is your doctor doing with this information to prevent your next stroke?
http://www.biosciencetechnology.com/news/2014/09/lost-protein-could-prevent-hardening-arteries?
Researchers have found that when the protein matrix metalloproteinase-14 (MMP-14) is reduced or lost, white blood cells, known as macrophages, become good and could prevent hardening of the arteries, rupture and sudden death.

The study, led by Dr. Jason Johnson, senior research fellow in the University of Bristol’s School of Clinical Sciences, is published in Arteriosclerosis, Thrombosis and Vascular Biology and was funded by the British Heart Foundation (BHF).